What is the appropriate management for esophageal candidiasis and erosive gastritis with a rapid urease test‑positive Helicobacter pylori infection?

Management of Esophageal Candidiasis with Erosive Gastritis and H. pylori Infection

Treat both conditions concurrently: initiate fluconazole 200-400 mg daily for 14-21 days for the esophageal candidiasis while simultaneously starting bismuth quadruple therapy for 14 days to eradicate H. pylori. 1, 2

Treatment Algorithm

For Esophageal Candidiasis

First-line therapy:

• Fluconazole 200-400 mg (3-6 mg/kg) daily for 14-21 days is the preferred treatment 1
• This is superior to other azoles and provides rapid symptom relief, typically within 7 days
• Most patients can tolerate oral therapy, making this the practical choice

Alternative options if fluconazole cannot be used:

• Itraconazole solution 200 mg daily for 14-21 days 1
• Amphotericin B deoxycholate 0.3-0.7 mg/kg daily (for those unable to take oral medications) 1

For fluconazole-refractory disease (if initial treatment fails):

• Voriconazole 200 mg (3 mg/kg) twice daily for 14-21 days, OR
• Echinocandins (micafungin 150 mg daily, caspofungin 70 mg loading then 50 mg daily, or anidulafungin 200 mg daily) for 14-21 days 1

For H. pylori-Associated Erosive Gastritis

First-line empiric therapy (when antibiotic susceptibility unknown):

• Bismuth quadruple therapy (BQT) for 14 days is the preferred regimen 2
• This consists of: proton pump inhibitor (PPI) + bismuth + tetracycline + metronidazole
• The PPI component will simultaneously help heal the erosive gastritis

Alternative first-line options:

• Rifabutin triple therapy for 14 days (if no penicillin allergy) 2
• Potassium-competitive acid blocker dual therapy for 14 days 2

Critical Clinical Considerations

Why treat both simultaneously:

• H. pylori eradication is essential for long-term healing of erosive gastritis 3, 4
• Studies show 100% prevalence of H. pylori in erosive duodenitis, and eradication correlates directly with erosion healing (86% vs 37% without eradication) 3
• The PPI component of H. pylori therapy provides acid suppression that benefits both conditions
• There are no significant drug interactions between fluconazole and standard H. pylori regimens

Post-treatment management:

• Confirm H. pylori eradication 4-6 weeks after completing therapy using urea breath test or stool antigen test (NOT serology) 5, 2
• If esophageal symptoms persist beyond 7 days, consider endoscopy to reassess candidiasis and rule out fluconazole resistance 1
• Repeat endoscopy 1 month after treatment to confirm healing of erosive gastritis if clinically indicated

Common Pitfalls to Avoid

Do not use clarithromycin-based triple therapy as first-line unless local resistance rates are known to be <15% - this is rarely the case in North America 2

Do not use echinocandins as first-line for esophageal candidiasis - while effective, they have higher relapse rates than fluconazole and require IV administration 1

Do not rely on serologic testing to confirm H. pylori cure - serology remains positive for months to years after eradication 6

Do not assume erosive gastritis will heal with acid suppression alone - H. pylori eradication is the definitive treatment, with multivariate analysis showing it as the only variable correlating with erosion healing 3

If Initial H. pylori Treatment Fails

For treatment-experienced patients with persistent infection:

• Use "optimized" BQT for 14 days if not previously used 2
• If previously treated with optimized BQT, use rifabutin triple therapy for 14 days 2
• Consider antibiotic susceptibility testing to guide salvage therapy 5, 2
• Avoid clarithromycin or levofloxacin-based regimens unless susceptibility is confirmed 2

The likelihood of successful eradication decreases with each subsequent attempt, making first-line treatment selection critical 5